We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Vaxart Inc is a biotechnology business with stocks listed in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$8.17 – a decrease of 2.85% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$3.71 - US$15.8 |
|---|---|
| 50-day moving average | US$8.6566 |
| 200-day moving average | US$7.4433 |
| Target price | US$12.5 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-0.476 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $8.17
| 1 week (2021-09-16) | -0.61% |
|---|---|
| 1 month (2021-08-26) | -9.32% |
| 3 months (2021-06-25) | -4.33% |
| 6 months (2021-03-26) | 36.39% |
| 1 year (2020-09-25) | 10.41% |
|---|---|
| 2 years (2019-09-26) | 2,669.49% |
| 3 years (2018-09-26) | 187.68% |
| 5 years (2016-09-26) | -60.07% |
| Revenue TTM | US$1.2 million |
|---|---|
| Gross profit TTM | US$-15,817,000 |
| Return on assets TTM | -22.69% |
| Return on equity TTM | -45.05% |
| Profit margin | 0% |
| Book value | 1.627 |
| Market capitalisation | US$1 billion |
TTM: trailing 12 months
There are currently 17.4 million Vaxart shares held short by investors – that's known as Vaxart's "short interest". This figure is 14.6% down from 20.3 million last month.
There are a few different ways that this level of interest in shorting Vaxart shares can be evaluated.
Vaxart's "short interest ratio" (SIR) is the quantity of Vaxart shares currently shorted divided by the average quantity of Vaxart shares traded daily (recently around 8.6 million). Vaxart's SIR currently stands at 2.02. In other words for every 100,000 Vaxart shares traded daily on the market, roughly 2020 shares are currently held short.
However Vaxart's short interest can also be evaluated against the total number of Vaxart shares, or, against the total number of tradable Vaxart shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaxart's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Vaxart shares in existence, roughly 140 shares are currently held short) or 0.1426% of the tradable shares (for every 100,000 tradable Vaxart shares, roughly 143 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaxart.
Find out more about how you can short Vaxart stock.
We're not expecting Vaxart to pay a dividend over the next 12 months.
Vaxart's shares were split on a 1:11 basis on 13 February 2018. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.
Over the last 12 months, Vaxart's shares have ranged in value from as little as US$3.71 up to US$15.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is 0.3903. This would suggest that Vaxart's shares are less volatile than average (for this exchange).
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Everything we know about the Cosmos Exploration IPO, plus information on how to buy in.
Shares in BNPL provider Zip Co have slipped more than 13% in the last 6 months.
Shares in electricity giant AGL Energy are down 60% in the last 12 months.
Everything we know about the Dundas Minerals IPO, plus information on how to buy in.
Everything we know about the Kalgoorlie Gold Mining IPO, plus information on how to buy in.
We look at some of the biggest and best performing iron ore stocks in Australia.
Shares in the major banks have risen more than 50% in the last 12 months.
Steps to owning and managing China Evergrande Group shares from Australia.
Virgin Australia launches more direct Tassie services with flexible flights taking off from October 2021.
Everything we know about the Hamelin Gold IPO, plus information on how to buy in.
